GlassScriptPhysician profile
Rafael A Blasini
NPI 1942239611
$8,842.78
in general payments reported to CMS, 2019-2025
39 companies · $1,454 in 2025
The $1,454 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,046 · 2020: $1,023 · 2021: $465 · 2022: $989 · 2023: $1,380 · 2024: $1,486 · 2025: $1,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,206 · Education: $99.99 · Entertainment: $13.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,206.42 |
| Education | $99.99 |
| Entertainment | $13.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,237.90 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,087.26 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $952.11 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $632.66 | 2019-2025 | |
| Abbvie INC. | $619.28 | 2019-2025 | Ubrelvy, Synthroid, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $335.29 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $327.52 | 2019-2023 | |
| Astellas Pharma US INC | $302.19 | 2023-2025 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $246.01 | 2020-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.15 | 2019-2024 | Xifaxan, Ibschek |
| Medtronic, INC. | $186.24 | 2021-2024 | Reveal Linq |
| Janssen Pharmaceuticals, INC | $175.21 | 2019-2022 | |
| Amarin Pharma, INC. | $162.73 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.92 | 2019-2025 | Jardiance, Tradjenta |
| Amgen INC. | $129.88 | 2019-2025 | Repatha, Otezla, Repatha |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $114.01 | 2022-2025 | Id Now Instrument, Freestyle Libre 2, Freestyle Libre 3 |
| Allergan, INC. | $101.50 | 2019-2020 | |
| Glaxosmithkline, LLC. | $97.05 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $80.42 | 2019-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $78.74 | 2019-2021 | |
| Exact Sciences Corporation | $58.88 | 2023-2025 | Cologuard Collection Kit |
| Depuy Synthes Sales INC. | $58.04 | 2023 | Teligen |
| Takeda Pharmaceuticals U.S.A., INC. | $57.99 | 2019 | |
| Arbor Pharmaceuticals, INC. | $52.67 | 2019-2021 | |
| Xeris Pharmaceuticals, INC. | $47.15 | 2022 | |
| Merck Sharp & Dohme LLC | $43.02 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Intuitive Surgical, INC. | $34.50 | 2019 | |
| Idorsia Pharmaceuticals US INC | $31.31 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $30.88 | 2022 | |
| Currax Pharmaceuticals LLC | $29.23 | 2025 | Contrave |
| Hikma Pharmaceuticals USA | $23.33 | 2019 | |
| Azurity Pharmaceuticals, INC. | $20.72 | 2023 | Horizant |
| Otsuka America Pharmaceutical, INC. | $20.25 | 2025 | Rexulti |
| Boston Scientific Corporation | $19.04 | 2025 | Overstitch Endoscopic Suturing System |
| Sanofi Pasteur INC. | $18.81 | 2020 | |
| Nevro Corp. | $15.53 | 2024 | Senza |
| Lundbeck LLC | $15.16 | 2024 | Rexulti |
| Optos, INC. | $13.68 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Ibsa Pharma INC. | $12.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Blasini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.